<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="abstract"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Eur Psychiatry</journal-id><journal-id journal-id-type="iso-abbrev">Eur Psychiatry</journal-id><journal-id journal-id-type="publisher-id">EPA</journal-id><journal-title-group><journal-title>European Psychiatry</journal-title></journal-title-group><issn pub-type="ppub">0924-9338</issn><issn pub-type="epub">1778-3585</issn><publisher><publisher-name>Cambridge University Press</publisher-name><publisher-loc>Cambridge, UK</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11863007</article-id><article-id pub-id-type="doi">10.1192/j.eurpsy.2024.749</article-id><article-id pub-id-type="other">EPP0650</article-id><article-id pub-id-type="pii">S0924933824007491</article-id><article-categories><subj-group subj-group-type="heading"><subject>Abstract</subject></subj-group><subj-group subj-group-type="section"><subject>e-Poster Presentation</subject></subj-group></article-categories><title-group><article-title>Esketamine nasal spray shows greater improvement in health-related quality of life over 32 weeks versus quetiapine extended release in patients with treatment resistant depression</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Young</surname><given-names>A. H.</given-names></name><xref rid="aff1777" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff1778" ref-type="aff">
<sup>2</sup>
</xref><xref rid="cor0610" ref-type="corresp">
<sup>*</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Baune</surname><given-names>B. T.</given-names></name><xref rid="aff1779" ref-type="aff">
<sup>3</sup>
</xref><xref rid="aff1780" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Cardoner</surname><given-names>N.</given-names></name><xref rid="aff1781" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Frey</surname><given-names>R.</given-names></name><xref rid="aff1782" ref-type="aff">
<sup>6</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Ito</surname><given-names>T.</given-names></name><xref rid="aff1783" ref-type="aff">
<sup>7</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Kambarov</surname><given-names>Y.</given-names></name><xref rid="aff1784" ref-type="aff">
<sup>8</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Lacerda</surname><given-names>A.</given-names></name><xref rid="aff1785" ref-type="aff">
<sup>9</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Rive</surname><given-names>B.</given-names></name><xref rid="aff1786" ref-type="aff">
<sup>10</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>von Holt</surname><given-names>C.</given-names></name><xref rid="aff1787" ref-type="aff">
<sup>11</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Oliveira-Maia</surname><given-names>A. J.</given-names></name><xref rid="aff1788" ref-type="aff">
<sup>12</sup>
</xref><xref rid="aff1789" ref-type="aff">
<sup>13</sup>
</xref></contrib></contrib-group><aff id="aff1777"><sup>1</sup>Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, <institution>King&#x02019;s College London</institution>, <city>
London</city></aff><aff id="aff1778"><sup>2</sup><institution>South London and Maudsley NHS Foundation Trust</institution>, Bethlem Royal Hospital, <city>Beckenham</city>, <country>United Kingdom</country></aff><aff id="aff1779"><sup>3</sup>Department of Psychiatry, <institution>University of M&#x000fc;nster</institution>, <city>M&#x000fc;nster</city>, <country>Germany</country></aff><aff id="aff1780"><sup>4</sup>Department of Psychiatry, <institution>The University of Melbourne</institution>, <city>Melbourne</city>, <country>
Australia</country></aff><aff id="aff1781"><sup>5</sup><institution>Hospital de la Santa Creu i Sant Pau Universitat Aut&#x000f2;noma de Barcelona (UAB)</institution>, <city>Barcelona</city>, <country>Spain</country></aff><aff id="aff1782"><sup>6</sup>Department of Psychiatry and Psychotherapy, <institution>Medical University of Vienna</institution>, <city>Vienna</city>, <country>Austria</country></aff><aff id="aff1783"><sup>7</sup><institution>Janssen EMEA</institution>, High Wycombe, <country>United Kingdom</country></aff><aff id="aff1784"><sup>8</sup><institution>Janssen EMEA</institution>, <city>Beerse</city>, <country>Belgium</country></aff><aff id="aff1785"><sup>9</sup>Laborat&#x000f3;rio Interdisciplinar de Neuroci&#x000ea;ncias Cl&#x000ed;nicas, <institution>Universidade Federal de S&#x000e3;o Paulo</institution>, <city>S&#x000e3;o Paulo</city>, <country>Brazil</country></aff><aff id="aff1786"><sup>10</sup><institution>Janssen EMEA</institution>, <city>Paris</city>, <country>France</country></aff><aff id="aff1787"><sup>11</sup><institution>Janssen EMEA</institution>, <city>Neuss</city>, <country>Germany</country></aff><aff id="aff1788">
<sup>12</sup>
<institution>Champalimaud Research and Clinical Centre, Champalimaud Foundation</institution>
</aff><aff id="aff1789"><sup>13</sup>NOVA Medical School, Faculdade de Ci&#x000ea;ncias M&#x000e9;dicas, NMS, FCM, <institution>Universidade NOVA de Lisboa</institution>, <city>Lisbon</city>, <country>Portugal</country></aff><author-notes><corresp id="cor0610"><label>*</label>Corresponding author.</corresp></author-notes><pub-date publication-format="electronic" date-type="collection" iso-8601-date="2024-04"><month>4</month><year>2024</year></pub-date><pub-date pub-type="epub"><day>27</day><month>8</month><year>2024</year></pub-date><volume>67</volume><issue seq="724">Suppl 1</issue><issue-title content-type="special_issue">Abstracts of the 32nd European Congress of Psychiatry</issue-title><fpage>S363</fpage><lpage>S365</lpage><permissions><copyright-statement>&#x000a9; The Author(s) 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>The Author(s)</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (<uri xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</uri>), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:title="pdf" xlink:href="S0924933824007491a.pdf"/><abstract><sec id="sec3666"><title>Introduction</title><p>In ESCAPE-TRD esketamine nasal spray (ESK-NS) significantly increased the probability of achieving remission at Week (Wk) 8 and being relapse&#x02011;free through Wk32 after remission at Wk8 versus (vs) quetiapine extended release (Q-XR) in patients (pts) with treatment resistant depression (TRD) (Reif <italic toggle="yes">et al.</italic> DGPPN 2022; P-01-04). We report ESK-NS vs Q-XR effects on pt-reported health-related quality of life (HRQoL) over 32 wks.</p></sec><sec id="sec3667"><title>Objectives</title><p>Evaluate pt-reported HRQoL using the generic 36-item Short-Form Health Survey version 2 (SF-36v2, 4-wk recall, 2009 US population norms) in ESCAPE-TRD.</p></sec><sec id="sec3668"><title>Methods</title><p>ESCAPE&#x02011;TRD (NCT04338321) was a randomised phase IIIb trial comparing the efficacy of ESK-NS vs Q-XR, both alongside an ongoing selective serotonin/serotonin-norepinephrine reuptake inhibitor, in pts with TRD. SF-36v2 was assessed every 4 wks (on-treatment and retrieved dropout visits). Domain scores and change from baseline (CfB) were analysed using a mixed model for repeated measures (MMRM; observed cases) adjusted for age, prior treatment failures, baseline score. Higher scores indicate better HRQoL. P values were not adjusted for multiple testing.</p></sec><sec id="sec3669"><title>Results</title><p>336 and 340 pts were randomised to ESK-NS and Q-XR. Baseline domain scores were below general population norms and lowest in Role Emotional, Mental Health and Social Functioning (<bold>
Figure 1A</bold>). All scores improved to Wk32 in both arms (<bold>
Figure 1B</bold>). At Wk4, CfB was significantly higher (better HRQoL) with ESK-NS vs Q-XR across domains (all p&#x0003c;0.01). At Wk8, CfB was significantly higher with ESK-NS vs Q-XR across all domains (p&#x0003c;0.05) except Bodily Pain and Role Physical. At Wk32, CfB was significantly higher with ESK-NS vs Q-XR for Mental Health (p=0.014), Role Emotional (p=0.001), Role Physical (p=0.046) and Social Functioning (p=0.006); a trend of numerical advantage was seen for all other domains (<bold>
Figure 2</bold>).</p><p>
<bold>Image:</bold></p><p>
<fig position="float" id="fig0093"><graphic xlink:href="S0924933824007491-FIG0093" position="anchor"/></fig>
</p><p>
<bold>Image 2:</bold>
</p><p>
<fig position="float" id="fig0094"><graphic xlink:href="S0924933824007491-FIG0094" position="anchor"/></fig>
</p></sec><sec id="sec3670"><title>Conclusions</title><p>In addition to the superior clinical benefits provided by ESK-NS vs Q-XR in ESCAPE-TRD, pts receiving ESK-NS experienced significantly greater improvements in HRQoL vs Q-XR over 32 wks.</p></sec><sec id="sec3671"><title>Acknowledgements</title><p>We thank the patients who participated. Study funding: Janssen, medical writing: Costello Medical, UK.</p></sec><sec id="sec3672"><title>Disclosure of Interest</title><p>
A. Young Grant / Research support from: Received grants from Janssen; independent research funded by the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King&#x02019;s College London; the views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health, Consultant of: Received consulting fees from Allegan, AstraZeneca, Bionomics, Eli Lilly, Janssen, Johnson &#x00026; Johnson, LivaNova, Lundbeck, Servier, and Sumitomo Dainippon Pharma and Sunovion, Speakers bureau of: Received speaker&#x02019;s honoraria from Allegan, AstraZeneca, Bionomics, Eli Lilly, Janssen, Johnson &#x00026; Johnson, LivaNova, Lundbeck, Servier, and Sumitomo Dainippon Pharma and Sunovion, B. Baune Grant / Research support from: Received research grants from private industries or non-profit funds from AstraZeneca, Lundbeck, and Sanofi-Synth&#x000e9;labo; received research grants from the BMBF and BMG Germany, the DFG, Germany, the National Health and Medical Research Council, Australia, and Horizon Europe 2021; received research grants from the Fay Fuller Foundation, and James &#x00026; Diana Ramsay Foundation, Adelaide, Consultant of: Received consulting fees for roles with the National Health and Medical Research Council, Australia; received honoraria from Angelini, AstraZeneca, Biogen, BMS, Boehringer Ingelheim, Johnson &#x00026; Johnson, LivaNova, Lundbeck, Otsuka, Pfizer, Roche, Servier, Sumitomo Dainippon Pharma and Sunovion, and Wyeth; served on advisory boards for Biogen, Boehringer-Ingelheim, Janssen-Cilag, LivaNova, Lundbeck, Novartis, and Otsuka, N. Cardoner Grant / Research support from: Received research grants from the Ministry of Health, Ministry of Science and Innovation (CIBERSAM), and the Strategic Plan for Research and Innovation in Health (PERIS) for the period 2016&#x02013;2020, as well as from Marato TV3 and Recercaixa, Consultant of: Served on advisory boards for Angelini, Esteve, Janssen, Lundbeck, Novartis, Pfizer and Viatris, Speakers bureau of: Received speaker&#x02019;s honoraria from Angelini, Esteve, Janssen, Lundbeck, Novartis, Pfizer and Viatris, R. Frey Grant / Research support from: Received travel fees from Janssen and LivaNova; received grants or contracts from Alkermes (Principal Investigator), Janssen (Principal Investigator), LivaNova (Principal Investigator) and Medizinisch&#x02011;Wissenschaftlicher Fonds des B&#x000fc;rgermeisters von Wien (academic study), Consultant of: Received consulting fees from Boehringer Ingelheim and Janssen, Speakers bureau of: Received speaker&#x02019;s honoraria from Janssen and Lundbeck, T. Ito Shareolder of: Johnson &#x00026; Johnson, Employee of: Janssen, Y. Kambarov Employee of: Janssen, A. Lacerda Grant / Research support from: Received grants from Azidus, Biophytis, Boehringer-Ingelheim, Cellavita, Celltrion, CNPq, Eli Lilly, EOM, FAPESP, Genova, IQVIA, Janssen, Nordisk, Novartis, Novo, Parexel and PPD, Consultant of: Received consulting fees from Ach&#x000e9;, Apsen, Biogen, Boehringer-Ingelheim, Cristalia, Daiichi, Eurofarma, Sankyo, EMS, Janssen, Libbs, LivaNova, Lundbeck, Sanofi and Torrent, Speakers bureau of: Received speaker&#x02019;s honoraria from Ach&#x000e9;, Apsen, Biogen, Boehringer-Ingelheim, Cristalia, Daiichi, Eurofarma, Sankyo, EMS, Janssen, Libbs, LivaNova, Lundbeck, Sanofi and Torrent, B. Rive Employee of: Janssen, C. von Holt Shareolder of: Johnson &#x00026; Johnson, Employee of: Janssen, A. Oliveira-Maia Grant / Research support from: Received grants from Compass Pathways, Ltd., Janssen, and Schuhfried GmBH; investigator&#x02011;driven research funded by Funda&#x000e7;&#x000e3;o para Ci&#x000ea;ncia e Tecnologia (PTDC/SAU-NUT/3507/2021; PTDC/MED-NEU/1552/2021; PTDC/MED&#x02011;NEU/31331/2017), Funda&#x000e7;&#x000e3;o para Ci&#x000ea;ncia e Tecnologia and FEDER (PTDC/MED-NEU/30845/2017_LISBOA-01-0145-FEDER-030845; PTDC/MEC-PSQ/30302/2017_LISBOA-01-0145-FEDER-30302), the European Research Council (ERC-2020-STG-Grant 950357), the European Commission Horizon 2020 Research and Innovation program (H2020&#x02011;SC1&#x02011;
2017&#x02011;CNECT&#x02011;2&#x02011;777167&#x02011;&#x00392;&#x0039f;UNCE; H2020&#x02011;SC1&#x02011;DTH&#x02011;2019&#x02011;875358&#x02011;FAITH), and the European Joint Programme in Rare Diseases (Joint 
Translational Call 2019) through Funda&#x000e7;&#x000e3;o para Ci&#x000ea;ncia e Tecnologia (EJPRD/0001/2020), Consultant of: Received payment or honoraria from MSD (Portugal), Neurolite AG, and the European Monitoring Centre for Drugs and Drug Addiction; received support for attending meetings from Janssen (Portugal); participated in advisory boards for Angelini (Portugal) and Janssen (Portugal), Employee of: Vice-President of the Portuguese Society for Psychiatry and Mental Health; Head of the Psychiatry Working Group for the National Board of Medical Examination (GPNA) at the Portuguese Medical Association and Portuguese Ministry of Health</p></sec></abstract><counts><page-count count="3"/></counts></article-meta></front></article>